“…In many neuropsychiatric illnesses, including schizophrenia, sleep disorders and deficits in attention-related sensorimotor and cognitive integration processes are common. These disorders insidiously start to occur during the prodromal phase (McGhie & Chapman, 1961; Lunsford-Avery et al ., 2013; Manoach et al ., 2014; Zanini et al ., 2015; Mayeli et al ., 2021). Administration of the non-competitive NMDA receptor antagonist ketamine at a subanesthetic dose can, after the administration of a subanesthetic dose, induce a psychosis-relevant mental state in healthy humans (Krystal et al ., 1994; Hetem et al ., 2000; Anticevic et al ., 2015; Hoflich et al ., 2015; Rivolta et al ., 2015; Grent-’t-Jong et al ., 2018) and other species, including rodents (Chrobak et al ., 2008; Pinault, 2008; Pitsikas et al ., 2008; Ehrlichman et al ., 2009; Hakami et al ., 2009; Kocsis, 2012).…”